Get Ahead with IPO Insights, IPO Prophet

IPO Prophet

Get Ahead with IPO Insights

At IPO Prophet®, our team leverages over three decades of expertise to deliver actionable quantitative analytics for the IPO market in real-time. This platform synthesizes our extensive experience investing in IPOs, providing investors with revolutionary tools to navigate the complexities of issuance day. Our mission is to empower investors with data-driven insights to make more informed decisions.

Equity Capital Markets

Odyssey Therapeutics / Equity Capital Markets

<ul><li>Odyssey Therapeutics (ODTX) and Mobia Medical (MOBI) both struggled to generate meaningful Day-One momentum Friday, with neither deal producing a Bull signal despite very different opening setups.</li><li>Odyssey opened at a premium to its $18 IPO price, trading as high as $20.30 shortly after the open, but the move lacked the type of sustained institutional follow through typically associated with stronger IPO debuts.</li><li>IPO Prophet’s posture on ODTX was initially neutral during the opening trade before sentiment shifted bearish early in the session as momentum deteriorated and shares steadily faded throughout the afternoon, ultimately closing at $16.42.</li></ul>

Odyssey Therapeutics (ODTX) and Mobia Medical (MOBI) both struggled to generate meaningful Day-One momentum Friday, with neither deal producing a Bull signal despite very different opening setups.Odyssey opened at a premium to its $18 IPO price, trading as high as $20.30 shortly after the open, but the move lacked the type of sustained institutional follow through typically associated with stronger IPO debuts.IPO Prophet’s posture on ODTX was initially neutral during the opening trade before sentiment shifted bearish early in the session as momentum deteriorated and shares steadily faded throughout the afternoon, ultimately closing at $16.42.

IPO Market Sees Weak Day-One Follow Through as Odyssey Fades and Mobia Opens Under Pressure

US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

<ul>
<li>ODTX priced above expectations after upsizing, but broke issue price quickly as short-term IPO flippers overwhelmed aftermarket demand.</li>
<li>Shares closed down 8.8% on day one, signaling weak institutional support despite strong pre-IPO indications and quality shareholder backing.</li>
<li>Recovery from here likely depends on strong clinical data, improved biotech sentiment, and rebuilding long-only investor confidence over time.</li>
</ul>


ODTX priced above expectations after upsizing, but broke issue price quickly as short-term IPO flippers overwhelmed aftermarket demand.
Shares closed down 8.8% on day one, signaling weak institutional support despite strong pre-IPO indications and quality shareholder backing.
Recovery from here likely depends on strong clinical data, improved biotech sentiment, and rebuilding long-only investor confidence over time.


Odyssey Therapeutics, Inc.(ODTX): IPO Breaks Issue After Aggressive Upsizing

<ul><li>✅ IPO PROPHET RATING: 7.87/10 🏦 Deal Quality &amp; Underwriters: 9/10 Odyssey Therapeutics is coming to market as a clinical-stage biotechnology company focused on immunology and inflammation, targeting well-validated biological pathways with differentiated chemistry and selectivity.</li><li>The deal is expected to be sized in the ~$200–$250 million range and is being positioned as a high-quality institutional biotech offering.The syndicate is as strong as it gets for a biotech IPO, with Goldman Sachs, J.P.</li><li>Morgan, and Morgan Stanley leading the deal.</li></ul>

✅ IPO PROPHET RATING: 7.87/10 🏦 Deal Quality &amp; Underwriters: 9/10 Odyssey Therapeutics is coming to market as a clinical-stage biotechnology company focused on immunology and inflammation, targeting well-validated biological pathways with differentiated chemistry and selectivity.The deal is expected to be sized in the ~$200–$250 million range and is being positioned as a high-quality institutional biotech offering.The syndicate is as strong as it gets for a biotech IPO, with Goldman Sachs, J.P.Morgan, and Morgan Stanley leading the deal.

<ul>
<li>Odyssey Therapeutics, Inc . has set terms for its initial public offering, marketing 13.24 million shares at a price range of $16 to $18 , implying a deal size of approximately $225 million at the midpoint .</li>
<li>The company plans to list on the Nasdaq under the ticker ODTX, with J.P. Morgan, TD Cowen, and Cantor leading the offering alongside Wedbush, PacGrow, and Oppenheimer.</li>
<li>Based on an assumed midpoint pricing, Odyssey would have an estimated post-offer market capitalization of roughly $760–$800 million (depending on final share count and concurrent private placement assumptions).</li>
</ul>


Odyssey Therapeutics, Inc . has set terms for its initial public offering, marketing 13.24 million shares at a price range of $16 to $18 , implying a deal size of approximately $225 million at the midpoint .
The company plans to list on the Nasdaq under the ticker ODTX, with J.P. Morgan, TD Cowen, and Cantor leading the offering alongside Wedbush, PacGrow, and Oppenheimer.
Based on an assumed midpoint pricing, Odyssey would have an estimated post-offer market capitalization of roughly $760–$800 million (depending on final share count and concurrent private placement assumptions).


Odyssey Therapeutics Sets Terms for $225M IPO as Immunology Platform Targets Breakthroughs in Autoimmune Disease

<ul>
<li>Lead asset OD-001 shows Phase 2a proof-of-concept in ulcerative colitis, providing a relatively advanced pipeline versus typical biotech IPOs.</li>
<li>Backing from top-tier investors and a $25M concurrent private placement reinforces confidence and supports aftermarket stability.</li>
<li>Risk-Reward skews positive despite prior IPO delay, supported by strong demand, credible leadership, and improving biotech market conditions.</li>
</ul>


Lead asset OD-001 shows Phase 2a proof-of-concept in ulcerative colitis, providing a relatively advanced pipeline versus typical biotech IPOs.
Backing from top-tier investors and a $25M concurrent private placement reinforces confidence and supports aftermarket stability.
Risk-Reward skews positive despite prior IPO delay, supported by strong demand, credible leadership, and improving biotech market conditions.


Odyssey Therapeutics, Inc.(ODTX): Solid Demand Meets Advanced Immunology Pipeline

United States

Clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that are designed to precisely target disease pathology

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Odyssey Therapeutics (ODTX US)

IPO Market Sees Weak Day-One Follow Through as Odyssey Fades and Mobia Opens Under Pressure

Odyssey Therapeutics (ODTX) and Mobia Medical (MOBI) both struggled to generate meaningful Day-One momentum Friday, with neither deal producing a...

IPO Prophet

Odyssey Therapeutics, Inc.(ODTX): IPO Breaks Issue After Aggressive Upsizing

ODTX IPO priced above expectations but quickly dropped due to short-term flippers, weak institutional support, recovery hinges on clinical data...

IPO Boutique

IPO Rating: Odyssey Therapeutics, Inc.

✅ IPO PROPHET RATING: 7.87/10 🏦 Deal Quality & Underwriters: 9/10 Odyssey Therapeutics is coming to market as a clinical-stage biotechnology...

IPO Prophet

Odyssey Therapeutics Sets Terms for $225M IPO as Immunology Platform Targets Breakthroughs in Autoimmune Disease

Odyssey Therapeutics, Inc . has set terms for its initial public offering, marketing 13.24 million shares at a price range of $16 to $18 ,...

IPO Prophet

Odyssey Therapeutics, Inc.(ODTX): Solid Demand Meets Advanced Immunology Pipeline

Odyssey Therapeutics demonstrates promise in ulcerative colitis, with strong investor backing and positive market conditions supporting its...

IPO Boutique

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

IPO Market Sees Weak Day-One Follow Through as Odyssey Fades and Mobia Opens Under Pressure

Odyssey Therapeutics (ODTX) and Mobia Medical (MOBI) both struggled to generate meaningful Day-One momentum Friday, with neither deal producing a...

IPO Prophet

Odyssey Therapeutics, Inc.(ODTX): IPO Breaks Issue After Aggressive Upsizing

​ODTX IPO priced above expectations but quickly dropped due to short-term flippers, weak institutional support, recovery hinges on clinical data...

IPO Boutique

IPO Rating: Odyssey Therapeutics, Inc.

✅ IPO PROPHET RATING: 7.87/10 🏦 Deal Quality & Underwriters: 9/10 Odyssey Therapeutics is coming to market as a clinical-stage biotechnology...

IPO Prophet

Odyssey Therapeutics Sets Terms for $225M IPO as Immunology Platform Targets Breakthroughs in Autoimmune Disease

Odyssey Therapeutics, Inc . has set terms for its initial public offering, marketing 13.24 million shares at a price range of $16 to $18 ,...

IPO Prophet

Odyssey Therapeutics, Inc.(ODTX): Solid Demand Meets Advanced Immunology Pipeline

Odyssey Therapeutics demonstrates promise in ulcerative colitis, with strong investor backing and positive market conditions supporting its...

IPO Boutique

ODTX IPO priced above expectations but quickly dropped due to short-term flippers, weak institutional support, recovery hinges on clinical data...